AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders

著录项

• 来源
  《British Journal of Haematology》 |2010年第1期|p.46-57|共12页
• 作者

  Mark A. Dawson; Jayne E. Curry; Kelly Barber; Philip A. Beer; Brent Graham; John F. Lyons; Caroline J. Richardson; Mike A. Scott; Tomoko Smyth; Matthew S. Squires; Neil T. Thompson; Anthony R. Green; Nicola G. Wallis;

  展开▼
• 作者单位

  Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge|Addenbrooke’s Hospital, NHS Trust, University of Cambridge;

  |Astex Therapeutics Ltd, Cambridge Science Park, Cambridge, UK;

  |Addenbrooke’s Hospital, NHS Trust, University of Cambridge;

  Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge|Addenbrooke’s Hospital, NHS Trust, University of Cambridge;

  Astex Therapeutics Ltd, Cambridge Science Park, Cambridge, UK;

  Astex Therapeutics Ltd, Cambridge Science Park, Cambridge, UK;

  Astex Therapeutics Ltd, Cambridge Science Park, Cambridge, UK;

  Addenbrooke’s Hospital, NHS Trust, University of Cambridge;

  Astex Therapeutics Ltd, Cambridge Science Park, Cambridge, UK;

  Astex Therapeutics Ltd, Cambridge Science Park, Cambridge, UK;

  Astex Therapeutics Ltd, Cambridge Science Park, Cambridge, UK;

  Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge|Addenbrooke’s Hospital, NHS Trust, University of Cambridge;

  Astex Therapeutics Ltd, Cambridge Science Park, Cambridge, UK;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种
• 中图分类
• 关键词

  Janus kinase 2; Aurora kinase; myeloproliferative disorder; kinase inhibitor; Jak-dependent signalling;

  机译：Janus激酶2;Aurora激酶;骨髓增生异常;激酶抑制剂;Jak依赖性信号传导;